| Literature DB >> 34574476 |
Zuzanna Nowak1, Maciej Chęciński2, Aleksandra Nitecka-Buchta1, Sylwia Bulanda3, Danuta Ilczuk-Rypuła3, Lidia Postek-Stefańska3, Stefan Baron1.
Abstract
BACKGROUND: Myofascial pain is an important cause of disability among the whole population, and it is a common symptom of temporomandibular joint disorders (TMDs). Its management techniques vary widely; however, in recent years, there has been a growing interest especially in needling therapies within masticatory muscles, due to their simplicity and effectiveness in pain reduction.Entities:
Keywords: Botox; dry needling; intramuscular injections; myofascial pain; temporomandibular disorders; wet needling
Mesh:
Year: 2021 PMID: 34574476 PMCID: PMC8465617 DOI: 10.3390/ijerph18189552
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Applied search strategies.
| Search Strategy | |
|---|---|
| PubMed | (masseter OR temporalis OR lateral pterygoid OR medial pterygoid OR masticatory OR mastication) AND (muscle OR muscles OR intra-muscular OR intramuscular OR intra muscular OR trigger points) AND (injection OR injections OR puncture OR punctures OR administration OR needling OR dry needling OR acupuncture) AND (pain OR discomfort OR myofascial pain OR antinociceptive OR anti-nociceptive) AND (therapy OR treatment OR management OR pharmacotherapy OR diagnosis OR diagnostic OR diagnostics) AND (technique OR techniques OR method OR methods OR protocol OR protocols OR guidelines) |
| BASE | (masseter OR temporalis OR pterygoid OR masticatory OR mastication) AND (muscle OR muscles OR intra-muscular OR intramuscular OR intra muscular OR trigger points) AND (injection OR injections OR puncture OR punctures OR administration OR needling OR dry needling OR acupuncture) AND (pain OR discomfort OR myofascial pain OR antinociceptive OR anti-nociceptive) AND (therapy OR treatment OR management OR pharmacotherapy OR diagnosis OR diagnostic OR diagnostics) AND (technique OR techniques OR method OR methods OR protocol OR protocols OR guidelines) |
The eligibility criteria according to PICOS [16].
| Inclusion Criteria | Exclusion Criteria | |
|---|---|---|
| Population | Adult patients with myofascial orofacial pain according to the RDC/TMD or DC/TMD or ICOP | Animal patients, patients suffering with fibromyalgia, neuralgia, oromandibular dystonia, cerebral palsy, hypertrophic masseter muscles, clinically induced pain |
| Intervention | Intramuscular injections into masticatory muscles, dry needling of masticatory muscles | Intramuscular injections into other than masticatory muscles, nerve blockades, acupuncture |
| Comparison | Any or none | - |
| Outcome | Primary outcome: Effective penetration of the masticatory muscle in the course of its needling. Secondary outcome: Any positive treatment outcome (eg. pain decrease, increase in maximum mouth opening, pressure pain threshold increase, MTPs desactivation etc.) | - |
| Study design | Primary studies with an evidence level 1 to 3; description of the needling technique | Papers published prior to 2011; non-English articles |
Figure 1A PRISMA flow diagram of the literature screening and selection processes [19].
Studies regarding masseter muscle injections.
| Author, Year of Publication | Study Group Size | Wet/Dry Needling | Navigation Method or | Needle Penetration Spot(s) | Amount of Injected Substance | Number of Treatment Sessions |
|---|---|---|---|---|---|---|
| Al-Wayli, 2017 [ | 25 | BTX | manual palpation; deposition spots located regularly in the lower part of the muscle | 3 sites | 20 IU | 1 |
| Ananthan, 2019 [ | 25 | LA | digital palpation | MTPs | ns | 1 |
| Chaurand, 2020 [ | 22 | BTX | digital palpation | 2 sites | 30 IU | 1 |
| Chaurand, 2017 [ | 11 | BTX | manual palpation; one spot near mandibular angle and one near zygomatic arch | 2 sites | 20 IU | 1 |
| Ernberg, 2011 [ | 21 | BTX | EMG; 15 mm deep | 3 sites | 50 IU | 2 |
| Ghavimi, 2019 [ | 61 | BTX | manual palpation; deposition spots located regularly along the long axis of the muscle; | 3 sites | 50 IU | 1 |
| Guarda-Nardini, 2012 [ | 15 | BTX | manual palpation; 2 cm skin surface over most prominent area of the muscle after clenching | minimum 5 sites in reverse pyramid pattern | ns | 1 |
| Hosgor, 2020 [ | 44 | BTX | manual palpation | 3 sites | 150 IU | 1 |
| Ivask,2016 [ | 20 | BTX | manual palpation; most painful spot | 5 sites | ns | 1 |
| Kang, 2018 [ | 24 | LA | manual palpation; most painful spot | 1 site | 0.3 mL | 1 |
| Kang, 2018 [ | 11 | LA | manual palpation; most painful spot | 1 site | 0.3 mL | 1 |
| Kim, 2016 [ | 21 | BTX | manual palpation | 3 sites | 150 IU | 1 |
| Meral, 2019 [ | 25 | BTX | Ns | 6 sites | 24 IU | 1 |
| Nitecka-Buchta, 2019 [ | 29 | PRP | manual palpation; | 3 MTPs near the origin, under zygomatic arch | 1.5 mL | 1 |
| Nitecka-Buchta, 2018 [ | 18 | collagen | manual palpation; | MTPs | 2 mL | 2 |
| Nitecka-Buchta, 2018 [ | 15 | LA | manual palpation; | MTPs | 2 mL | 2 |
| Ozden, 2018 [ | 20 | DDN | manual palpation and analogue algometer; | MTPs | - | 3 |
| Ozden, 2018 [ | 20 | SDN | manual palpation and analogue algometer; | MTPs | - | 3 |
| Patel, 2017 [ | 20 | BTX | EMG and monopolar electrode injection needle | ns | 50 IU | 1 |
| Pihut, 2016 [ | 42 | BTX | manual palpation, area of the greatest cross-section surface of both masseter bellies | ns | 21 IU | 1 |
| Pons, 2018 [ | 6 | BTX | manual palpation | 3 sites | 30 IU | 1 |
| Sipahi Calis, 2019 [ | 9 | BTX | EMG | ns | 30 IU | 1 |
| Taskesen, 2020 [ | 15 | DDN | manual palpation | MTPs | - | 2 |
| Taskesen, 2020 [ | 15 | LA | manual palpation | MTPs | 0.2 mL | 2 |
| Tesch, 2019 [ | 5 | DDN | manual palpation | MTPs | - | 3 |
| Uemoto, 2013 [ | 7 | LA | digital palpation; | MTPs | 0.25 mL | 4 |
| Uemoto, 2013 [ | 7 | DDN | digital palpation | MTPs | - | 4 |
| Villa, 2018 [ | 28 | BTX | Ns | 3 sites | 50 IU | 1 |
| Yilmaz, 2020 [ | 26 | BTX | manual palpation | MTPs | 10 U/MTP | 1 |
| Yilmaz, 2020 [ | 27 | LA | manual palpation | MTPs | 0.5 mL/MTP | 1 |
| Yilmaz, 2020 [ | 29 | PRP | manual palpation | MTPs | 0.5 mL/MTP | 1 |
| Yurttutan, 2019 [ | 48 | BTX | manual palpation; deposition spots located regularly across the muscle mass | 5 sites | 30 IU | 1 |
Studies regarding temporal muscle injections.
| Author, Year of Publication | Study Group Size | Wet/Dry Needling | Navigation Method or | Needle Penetration Spot(s) | Amount of Injected Substance | Number of Treatment Sessions |
|---|---|---|---|---|---|---|
| Ananthan, 2019 [ | 25 | LA | digital palpation | MTPs | ns | 1 |
| Chaurand, 2020 [ | 22 | BTX | digital palpation | 2 sites | 20 IU | 1 |
| Chaurand, 2017 [ | 11 | BTX | digital palpation | 1 MTP | 10 IU | 1 |
| Guarda-Nardini, 2012 [ | 15 | BTX | manual palpation; 2 cm skin surface over most prominent area of the muscle after clenching | multiple injections in chess-board pattern | ns | 1 |
| Hosgor, 2020 [ | 44 | BTX | manual palpation | 2 sites | 100 IU | 1 |
| Ivask, 2016 [ | 20 | BTX | manual palpation; most painful spot | 5 sites | ns | 1 |
| Kim, 2016 [ | 21 | BTX | manual palpation | 3 sites | 100 IU | 1 |
| Meral, 2019 [ | 25 | BTX | Ns | 3 sites | 12 IU | 1 |
| Patel, 2017 [ | 20 | BTX | EMG and monopolar electrode injection needle | ns | 25 IU | 1 |
| Pons, 2018 [ | 6 | BTX | manual palpation | 2 sites | 20 IU | 1 |
| Sipahi Calis, 2019 [ | 9 | BTX | EMG | ns | 20 IU | 1 |
| Villa, 2018 [ | 28 | BTX | Ns | 2 sites | 25 IU | 1 |
| Yurttutan, 2019 [ | 48 | BTX | Ns | 3 sites | 15 IU | 1 |
Studies regarding lateral pterygoid muscle injections.
| Author, Year of Publication | Study Group Size | Wet/Dry Needling | Navigation Method or | Needle Penetration Spot(s) | Amount of Injected Substance | Number of Treatment Sessions |
|---|---|---|---|---|---|---|
| Gonzalez-Perez, 2015 [ | 24 | DDN | manual palpation; proper puncture confirmed by jump reaction or local twitch response | MTPs | - | 3 |
| Lopez-Martos, 2018 [ | 20 | DDN | EPI ® electrotherapy equipment | MTPs | - | 3 |
| Lopez-Martos, 2018 [ | 20 | PNE | EPI ® electrotherapy equipment | MTPs | - | 3 |
| Patel, 2017 [ | 20 | BTX | EMG and monopolar electrode injection needle | ns | 10 IU | 1 |
| Pons, 2018 [ | 6 | BTX | MRI infrared navigation; center of the upper head; about 33 mm from the skin | 1 site | 20 IU | 1 |
Studies regarding medial pterygoid muscle injections.
| Author, Year of Publication | Study Group Size | Wet/Dry Needling | Navigation Method or | Needle Penetration Spot(s) | Amount of Injected Substance | Number of Treatment Sessions |
|---|---|---|---|---|---|---|
| Mesa-Jimenez, 2020 [ | 5 | DDN | needle insertion at the inferior angle of the mandibular bone, parallelly to the mandible, advanced from an inferior to superior direction to maximum 30 mm; | medial surface of the inferior angle of the mandible | - | 1 |
Figure 2The number of interventions in the form of needling of each of the masticatory muscles in relation to the total number of patients included in the analyzed material.
Figure 3The share of substances injected into the masseter muscles and dry needling in relation to the number of analyzed trials.
Figure 4Navigational methods in needling of the masticatory muscles in relation to the number of analyzed studies.